There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Longboard Pharmaceuticals (LBPH – Research Report) and Phathom Pharmaceuticals (PHAT – Research Report) with bullish sentiments.
Longboard Pharmaceuticals (LBPH)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Longboard Pharmaceuticals, with a price target of $60.00. The company’s shares closed last Friday at $18.16.
According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of
Longboard Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $41.88, representing a 124.6% upside. In a report issued on March 12, Citi also maintained a Buy rating on the stock with a $40.00 price target.
See today’s best-performing stocks on TipRanks >>
Phathom Pharmaceuticals (PHAT)
Needham analyst Joseph Stringer maintained a Buy rating on Phathom Pharmaceuticals today and set a price target of $26.00. The company’s shares closed last Friday at $7.93.
According to TipRanks.com, Stringer is a 3-star analyst with an average return of
Phathom Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $21.33, a 172.4% upside from current levels. In a report issued on March 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $28.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LBPH:
- Longboard Pharmaceuticals Embarks on Risky Global Expansion Amid Regulatory Hurdles and Market Instability
- Longboard Pharmaceuticals files automatic mixed securities shelf
- Longboard Pharmaceuticals Shares Key Corporate Presentation
- Longboard Pharmaceuticals reports FY23 EPS ($2.39), consensus ($2.40)
- Longboard Pharmaceuticals Inc trading resumes
